Full-Time

Senior Director – Global Medical Review Lead

Posted on 5/9/2026

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$250k - $388.1k/yr

+ Incentive Opportunity

Princeton, NJ, USA

In Person

Must be available on-site; travel up to 25% internationally.

Category
Biology & Biotech (1)
Required Skills
Risk Management
Google Cloud Platform
Requirements
  • Strong knowledge of global regulatory guidelines pertaining to pharmacovigilance
  • Strong knowledge of MedDRA and any safety databases
  • Strong medical background evidenced by clinical training
  • Extensive experience interacting with global regulatory authorities and representing inspections
  • Solid knowledge of FDA and Global PV regulations
  • Knowledge of clinical trials, good clinical practices, and ICH guidelines
  • Experience working in a global and cross-functional pharma setting
  • M.D. from an accredited medical school with at least 8-10+ years of Safety Surveillance experience in pharmaceutical industry
  • Experience with both development and product launch/post marketed products
  • Acted as in-house authority/leader in Safety and Pharmacovigilance, and accountable for Safety of assigned products.
  • Experience interacting with global regulatory authorities such as EMA, MHRA, PMDA, Health Canada
  • Prior supervisory and vendor oversight experience
Responsibilities
  • Represents GPV Medical Safety department from a medical review standpoint as the key stakeholder in internal, external and health authority inspections, to ensure and sustain inspection readiness.
  • Defines and drives the global vision and strategic direction for Medical Review, ensuring alignment with evolving regulatory requirements, industry best practices, and the overarching objectives of the Global Medical Safety organization.
  • Leads the creation, revisioning and implementation of medical review Standard Operating Procedures, Work Practices, Job Aids and other guidance documents relevant to medical review. Drives adoption of best practices and continuous improvement initiatives.
  • Mentors and develops a high-performing team of medical reviewers, fostering a culture of accountability, innovation, and professional growth.
  • Oversees medical review of Individual Case Safety Reports (ICSRs) as the global medical review lead to ensure quality and accuracy of ICSRs by implementing and overseeing key performance metrics. Implement corrective actions and improvement plans as needed.
  • Chairs periodic global medical review meetings with the attendance of in-house, subsidiary, partner, and vendor medical reviewers.
  • Provides strong leadership and oversight of vendor activities related to the Medical review function, ensuring alignment with Otsuka’s standards and regulatory expectations.
  • Provides oversight of the safety profile of Otsuka products (both drugs and devices) through monitoring safety data, conducting risk analysis, and monitoring adverse events according to GCP and regulatory guidelines, to protect the safety of the patients and consumers and the company from legal implications.
  • Supports on development, implementation, and maintenance of GPV signal detection process.
  • Works in conjunction with related departments to develop and maintain a signal detection plan for use in all product life cycles.
  • Works with Medical safety Product leaders and represents MR at Labeling Committee/ Executive Committee discussions on new information impacting product profile.
  • Keeps abreast of industry standards and initiatives regarding signal detection, risk management, and risk communication.
  • Manages the continuous analysis of adverse events to identify safety signals and trends for assigned products.
  • Performs review and approval of the clinical trial medical coding.
  • Serves as back-up product/ medical monitor to coordinate clinical study safety and spontaneous reporting of assigned Otsuka products.
  • Maintains accurate and complete knowledge of assigned investigational and marketed products being monitored by Otsuka, co-marketers, co-sponsors, and/ or affiliates.
  • Works closely with PV Operations, Safety Database Management, Compliance Business Management and other PV functions.
  • Maintains a thorough understanding of internal and external interactions, and scope of work assigned to GPV Medical Safety and PV Operations departments.
  • Meets routinely with product specific GPV team members to review product safety issues.
  • Reviews each product (e.g., IND/NDA Periodic, CSR, Summary Analysis, etc.) and accompanying data for completeness, consistency, accuracy, and clarity.
  • Prepares/review safety summaries for inclusion in medical information write-ups, including analysis of similar events in alert reports.
  • Discusses safety issues with personnel in therapeutic specialty groups at meetings with vendors, licensing partners, agents, contract research organizations, and clinical site investigators.
  • Acts as the principal liaison for Medical review matters, collaborating closely with GPV Medical Safety Product Leaders, to engage with global regulatory agencies on product safety issues.
  • Demonstrates flexibility and responsiveness by being available on-site, even at short notice, to support urgent business needs, inspections, or regulatory engagements.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Simplify Jobs

Simplify's Take

What believers are saying

  • Voyxact achieves 82.5% hematuria improvement in IgAN trial at 48 weeks.
  • Acquired Transcend Therapeutics for $700M to advance psychiatric MDMA analog.
  • Partnered Keio University on May 8, 2025, for psychedelics infrastructure.

What critics are saying

  • AbbVie acquires Gilgamesh bretisilocin for $1.2B, leapfrogging Otsuka psychedelics.
  • Voyxact confirmatory trial fails kidney preservation in 18-24 months.
  • Japanese regulations block psychedelics trials in 24-36 months.

What makes Otsuka Pharmaceutical unique

  • Pioneered IV solutions in 1946, becoming Japan's top supplier.
  • Launched Pocari Sweat ion drink and Abilify antipsychotic globally.
  • Focuses on carbostyril-based original drugs since 1980.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Otsuka Pharmaceutical who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.

The Associated Press
Feb 6th, 2026
Sky Labs secures exclusive deal with Otsuka Pharmaceutical to launch ring-type blood pressure monitor in Japan

Sky Labs has signed an exclusive distribution agreement with Otsuka Pharmaceutical to launch its ring-type blood pressure monitor, CART BP pro, in Japan's hospital and clinic market. The deal follows an MoU signed in December 2024. CART BP pro uses photoplethysmography technology to measure blood pressure without a cuff, allowing comfortable monitoring during daily activities and sleep. The device has already achieved success in South Korea, with over 150,000 prescriptions across 1,700 medical institutions since its 2023 approval and national health insurance coverage in 2024. Japan's hypertension market includes approximately 43 million patients, with 29% failing to achieve blood pressure control and 33% unaware of their condition. Sky Labs will leverage Otsuka's distribution network and cardiovascular expertise to expand across Japanese healthcare facilities.